Compare AbCellera Biologics Inc (ABCL) vs Grab Holdings Ltd. (GRAB) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

GRAB trades at $3.93, up 0.77% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with net income of $268 million and revenue growth to $3.37 billion. Recent news highlights the departure of Uber's CEO from GRAB's board, causing a brief stock dip. Analyst consensus is strongly bullish with a $5.60 price target, representing significant upside potential from current levels.

GRAB's outlook is positive due to sustained revenue growth and recent profitability, though high P/E of 96.25 suggests elevated expectations. Key risks include competitive pressures in Southeast Asia and reliance on continued user growth. The stock offers growth exposure to the region's digital economy, supported by strong analyst buy ratings.